Last updated: March 11, 2021

Content on this page maintained by the Office of Cancer Genomics

CTD²: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD2) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy. 

Banner for CTD squared program. Links to CTD squared program page

News & Publications

View In the News Page
previousnext
Ovarian Cancer Stage IIIA
CTD²
April 01, 2021

Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma

Ovarian clear cell carcinoma (OCCC) is a rare, chemo-resistant subtype of ovarian cancer. To identify novel therapeutic targets and combination therapies for OCCC, we subjected a set of patient-derived ovarian cancer cell lines to arrayed high throughput siRNA and drug screening. The results...

DNA methylation patterns are stable at relapse except in a minority of cases.
CTD²
March 11, 2021

DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia

Acute myeloid leukemia (AML) is a molecularly complex disease characterized by heterogeneous tumor genetic profiles and involving numerous pathogenic mechanisms and pathways. Integration of molecular data types across multiple patient cohorts may advance current genetic approaches for improved...

Differentially regulated pathways between matched survival outliers.
CTD²
March 01, 2021

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype

Introduction: The clinical and biological significance of the newly described SCLC subtypes, SCLC-A, SCLC-N, SCLC-Y, and SCLC-P, defined by the dominant expression of transcription factors ASCL1, NeuroD1, YAP1, and POU2F3, respectively, remain to be established. Methods...

KRAS Protein Structure
CTD²
February 15, 2021

MEK inhibition remodels the immune landscape of mutant KRAS tumors to overcome resistance to PARP and immune checkpoint inhibitors

Mutant KRAS tumors are associated with poor outcomes at least in part due to decreased therapeutic sensitivity. Here we show that KRAS mutations are associated with resistance to monotherapy and combination therapy with Poly-(ADP-ribose) polymerase inhibitors (PARPi) and immune checkpoint...

O
O
O
O
O